Meldolesi Elisa, Chiloiro Giuditta, Giannini Roberta, Menghi Roberta, Persiani Roberto, Corvari Barbara, Coco Claudio, Manfrida Stefania, Ratto Carlo, De Luca Viola, Sofo Luigi, Reina Sara, Crucitti Antonio, Masiello Valeria, Dinapoli Nicola, Valentini Vincenzo, Gambacorta Maria Antonietta
Department of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Roma, Italy.
Digestive Surgery Unit, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy.
Cancers (Basel). 2022 Mar 24;14(7):1643. doi: 10.3390/cancers14071643.
Aims: Between 11 to 14% of patients with locally advanced rectal cancer (LARC) have positive lateral pelvic lymph nodes (LPLN) at diagnosis, related to a worse prognosis with a 5-year survival rate between 30 to 40%. The best treatment choice for this group of patients is still a challenge. The optimal radiotherapy (RT) dose for LPLN patients has been investigated. Methods: We retrospectively collected data from LARC patients with LPLN at the primary staging MRI, treated in our center from March 2003 to December 2020. Patients underwent a neoadjuvant concomitant chemo-radiotherapy (CRT) treatment on the primary tumor (T), mesorectum, and pelvic nodes, associated with a fluoride-based chemotherapy. The total reached dose was 45 Gy at 1.8 Gy/fr on the elective sites and 55 Gy at 2.2 Gy/fr on the disease and mesorectum. Patients were divided in two groups based on whether they received a simultaneous integrated RT boost on the LPLN or not. Overall Survival (OS), Disease Free Survival (DFS), Metastasis Free Survival (MFS), and Local Control (LC) were evaluated in the whole group and then compared between the two groups. Results: A total of 176 patients were evaluated: 82 were included in the RT boost group and 94 in the non-RT boost group. The median follow-up period was 57.8 months. All the clinical endpoint (OS, DFS, MFS, LC), resulted were affected by the simultaneous integrated boost on LPLN with a survival rate of 84.7%, 79.5%, 84.1%, and 92%, respectively, in the entire population. From the comparison of the two groups, there was a statistical significance towards the RT boost group with a p < 0.006, 0.030, 0.042, 0.026, respectively. Conclusions: Concomitant radiotherapy boost on positive LPLN has shown to be beneficial on the survival outcomes (OS, DFS, MFR, and LC) in patients with LARC and LPLN. This analysis demonstrates that a higher dose of radiotherapy on positive pelvic lymph nodes led not only to a higher local control but also to a better survival rate. These results, if validated by future prospective studies, can bring a valid alternative to the surgery dissection without the important side effects and permanent disabilities observed during the years.
局部晚期直肠癌(LARC)患者中,11%至14%在诊断时存在侧方盆腔淋巴结(LPLN)阳性,这与较差的预后相关,5年生存率在30%至40%之间。对于这组患者,最佳治疗选择仍是一项挑战。已对LPLN患者的最佳放疗(RT)剂量进行了研究。方法:我们回顾性收集了2003年3月至2020年12月在本中心接受治疗的、在初次分期MRI检查时发现有LPLN的LARC患者的数据。患者对原发肿瘤(T)、直肠系膜和盆腔淋巴结进行新辅助同步放化疗(CRT),并联合基于氟化物的化疗。在选择性部位,总剂量达到45 Gy,每次分割剂量为1.8 Gy;在病变和直肠系膜部位,总剂量达到55 Gy,每次分割剂量为2.2 Gy。根据患者是否接受对LPLN的同步整合放疗增敏,将患者分为两组。在整个队列中评估总生存期(OS)、无病生存期(DFS)、无转移生存期(MFS)和局部控制率(LC),然后在两组之间进行比较。结果:共评估了176例患者:82例纳入放疗增敏组,94例纳入非放疗增敏组。中位随访期为57.8个月。所有临床终点(OS, DFS, MFS, LC)均受到对LPLN的同步整合增敏的影响,在整个人群中,生存率分别为84.